CRX.L Regulatory News (CRX)

10 Oct 2005 07:00

Cyprotex PLC10 October 2005 Press Release 10 October 2005 CYPROTEX PLC ("Cyprotex" or "the Group") Directorate changes Cyprotex PLC (AIM: CRX) ("Cyprotex" or the "Group"), the provider ofpharmacokinetic technology and information, is pleased to announce the followingtwo board changes to support the Group's future development. Nikolas Sofronis, aged 40, is appointed as a Non-executive Director of the Groupwith immediate effect. Over the last 15 years, Nikolas has worked within thebiopharmaceuticals departments in several asset management organisations,including HSBC, Credit Lyonnais and the Republic Bank of New York. Nikolas isa graduate from the Athens Bar in Greece and is a lawyer by training. Dr. David Leahy will stand down from the board of Cyprotex to take up a newposition heading Cyprotex Research Limited, a newly created wholly ownedresearch facility of the Group. Cyprotex Research Limited will be charged withthe further development of the Group's predictive technology capabilities. Commenting on these new appointments, Robert Morrisson Atwater, Chairman andChief Executive Officer of Cyprotex, said: "The Directors would like to welcomeNikolas to the Board and at the same time thank David for his support andcounsel over the last couple of years. We are delighted that Nikolas and Davidhave taken up the challenge of these exciting new roles within the Group. I amsure that their contributions will both add significantly to the value of theenterprise." There are no further details to be announced pursuant to Schedule 2(g) of theAIM Rules for Companies. - Ends - For further information: Cyprotex PLCRobert Morrisson Atwater Tel: +44 (0) 1625 505 100 Chairman & Chief Executive Officerir@cyprotex.com www.cyprotex.com Code Securities LimitedChris Collins, Corporate Finance Tel: +44 (0) 20 7776 1200cic@codesecurities.com www.codesecurities.com Media enquiries: AbchurchHeather Salmond Tel: +44 (0) 20 7398 7700heather.salmond@abchurch-group.com www.abchurch-group.com Notes for Editors: Dr David Leahy joined ICI Pharmaceuticals (which subsequently became known asZeneca) in 1983 to work on computer models of drug action with a particularinterest in absorption and other pharmacokinetic properties. He was heavilyinvolved in the implementation of data mining approaches as well as 'virtualhuman' simulation models for the prediction of drug action in the whole animal. He was responsible for establishing higher throughput pharmacokinetic screeningand prediction approaches and led international multi-disciplinary teamsdeveloping strategies for the improvement of R&D productivity through technologyinnovation and process improvements. During his 15 years at ICI and Zeneca,David gained a detailed understanding of the drug discovery process. Davidfounded Cyprotex and is responsible for the science & technology of the Group. This information is provided by RNS The company news service from the London Stock Exchange